DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/l92tz4/viibryd_major) has announced the addition of the "Viibryd (Major Depressive Disorder) - Forecast and Market Analysis to 2023" report to their offering.
The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly's Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023.
Viibryd (vilazodone) is an SSRI and a 5HT1A receptor partial agonist indicated for the treatment of patients with MDD. Viibryd was licensed from Merck KGaA and developed by Forest (Actavis). Currently, it is only available in the US market and, in 2013, generated sales of $162.5m (Forest Laboratories, 2014).
- Overview of Major depressive disorder, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Viibryd including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Viibryd for the US from 2013 to 2023.
- Sales information covered for the US.
Key Topics Covered:
1 Tables & Figures
3 Disease Overview
4 Disease Management
5 Competitive Assessment
6 Viibryd (Vilazodone)
For more information visit http://www.researchandmarkets.com/research/l92tz4/viibryd_major